65 % of eligible lung cancer patients do not receive the most appropriate targeted therapies, Diaceutics report finds
News-Medical.net
Last updated: May 4, 2026
Diaceutics' new research highlights a significant shift in precision medicine, identifying a growing disconnect between the potential of diagnostic-driven therapies and their actual utilization. The study indicates that while the number of precision medicine therapies is rapidly increasing, the corresponding diagnostic testing is not keeping pace, creating a bottleneck in patient access. This gap is a critical challenge that needs to be addressed to fully realize the benefits of precision medicine.
- The research reveals a substantial growth in precision medicine therapies, with over 100 new therapies approved annually. However, the availability and accessibility of companion diagnostics are lagging significantly behind, impacting patient access to these life-changing treatments.
- A key finding is the increasing number of therapies that require specific genetic or molecular testing for effective patient selection. Despite this, a considerable percentage of patients who could benefit from these targeted treatments are not receiving the necessary diagnostic tests.
- The study points to various systemic issues contributing to this diagnostic gap, including challenges in reimbursement, regulatory hurdles for diagnostic tests, and a lack of awareness among healthcare professionals and patients.
- Diaceutics' analysis underscores the urgent need for improved infrastructure and collaboration among pharmaceutical companies, diagnostic providers, regulatory bodies, and healthcare systems to streamline the development and deployment of companion diagnostics.
- The ultimate goal is to ensure that patients can access the right treatment at the right time, driven by accurate and timely diagnostic information, thereby unlocking the full promise of precision medicine.
